Larimar Therapeutics Inc (LRMR)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Larimar Therapeutics Inc chart...

About the Company

Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for FA. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Employees

28

Exchange

NASDAQ

Website

larimartx.com

$M

Total Revenue

28

Employees

$38M

Market Capitalization

-0.78

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LRMR News

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

14d ago, source:

Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in ...

5 Stocks that Analysts Love in March 2024

10d ago, source: TipRanks on MSN

Today, we will look at 5 stocks that analysts are highly bullish about in March 2024. Analysts have recently given a Buy ...

Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks

8d ago, source:

In this article, we will take a detailed look at the Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks. For a ...

Larimar Triumphs: Significant Strides Made on the Road to Treating Friedreich's Ataxia

9d ago, source: MyChesCo on MSN

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR), a company dedicated to transforming the lives of patients ...

Buy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s Ataxia

16d ago, source:

LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on LRMR stock, giving a Buy rating today. Cory Jubinville, ...

Larimar: Q4 Earnings Snapshot

14d ago, source:

BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $13 million in its fourth quarter. On a per-share basis, the Bala Cynwyd, ...

Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results

14d ago, source:

Net Loss: Reported a net loss of $13.0 million in Q4 2023, and $36.9 million for the full year. Research and Development Expenses: Increased to $10.6 million in Q4 2023, primarily due to higher drug ...

Recap: Larimar Therapeutics Q4 Earnings

14d ago, source:

Larimar Therapeutics LRMR reported its Q4 earnings results on Thursday, March 14, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Larimar Therapeutics missed estimated ...

Altimmune falls after Q4 results; obesity drug data released

1d ago, source: Seeking Alpha on MSN

Altimmune (NASDAQ:ALT) shares lost ~21% premarket Wednesday after the company shared mid-stage data for its obesity candidate ...

Altimmune GAAP EPS of -$0.54 misses by $0.16

on MSN ago, source:

GAAP EPS of -$0.54 misses by $0.16. Revenues of $37K. Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...